Jingui Shenqi pill ( ) treats cardiorenal syndrome by inhibiting mitogen-activated protein kinase signaling pathway and reducing inflammatory response.

Objective: To confirm the therapeutic effect and mechanism of Jingui Shenqi pill (, JGSQP) on cardiorenal syndrome.

Methods: Doxorubicin was used to build heart-kidney coinjury rat model. After the modeling was completed, JGSQP gavage intervention was performed. The cardiac function of rats in each group was evaluated by ultrasound detection. Serum of rats was collected and examined for markers of heart and kidney damage. Enzyme linked immunosorbent assay detected serum inflammatory factors interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) expression. Quantitative real-time polymerase chain reaction (PCR) and Western blot detected the changes of related genes and proteins.

Results: JGSQP significantly increased left ventricular ejection fraction (EF) and left ventricular shortening fraction (FS) values, decreased the heart and kidney damage markers and fibrosis levels (P < 0.05). Furthermore, it can reduce IL-1β, IL-6, and TNF-α inflammatory expression (P < 0.05). Mechanistically, JGSQP significantly inhibited the expression of key genes and proteins of mitogen-activated protein kinase (MAPK) signaling pathway (P < 0.05).

Conclusions: Jingui Shenqi pill can exert therapeutic effects on cardiorenal syndrome by inhibiting the activation of the MAPK signaling pathway and inflammatory responses.